In my opinion this stock is clearly flying under the radar at...

In my opinion this stock is clearly flying under the radar at the moment. The preliminary results of the CP1 drug candidate appear very promising and bodes well for this company. Future trials studied on dogs are much less expensive than human clinical trials. Similarly, the approval of veterinary medicines is much swifter compared with human therapeutics. This may be a speculative investment, but there is considerable upside to this stock, given the rapid growth in domestic pets and the likewise, rapid growth of veterinary medications. This one may go all the way!
DYOR